353 related articles for article (PubMed ID: 35877035)
1. Inclisiran: How Widely and When Should We Use It?
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
3. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
4. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
6. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
7. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
[TBL] [Abstract][Full Text] [Related]
8. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
[TBL] [Abstract][Full Text] [Related]
9. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
10. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease.
Tomlinson B; Chow E; Chan P; Lam CWK
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1353-1361. PubMed ID: 35025707
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
13. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
14. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
16. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
17. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
18. First clinical experiences with inclisiran in a real-world setting.
Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
[TBL] [Abstract][Full Text] [Related]
19. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
20. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
